Novo Nordisk AS Class B

NOVO B: XCSE (DNK)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
LOCK|NHLOCK|$tLOCK|>?JKkN

Novo Nordisk: EU Approval of Wegovy Pill Expands Opportunity, but Cash Pay Raises Systematic Risk

Novo Nordisk received approval from the European Commission on July 15 to market the Wegovy pill as a treatment for obesity and overweight. Shares rose 3%.

Sponsor Center